Bispecific Antibody Discovery: Practical Strategies from MOA to Preclinical Candidates

• Advanced antibody discovery platforms for biology-driven lead identification
• Comprehensive in vitro functional assays across T-cell engagers (TCEs), immune checkpoint inhibitors, and autoimmune diseases
• Extensive in vivo efficacy models and well-established PK/PD/Tox platforms delivering time- and cost-effective solutions

Speakers:

Lily Zhao

Director, Scientific Advisor, CRO Service

WuXi Biologics